Gaois

Cóip statach de shonraí a easpórtáiltear ó IATE ó am go chéile atá sa chnuasach seo. Níor cheart glacadh leis gurb ionann i gcónaí an t-eolas a thugtar faoi iontráil anseo agus a bhfuil sa leagan reatha den iontráil ar IATE. Is féidir an leagan reatha sin a cheadú ach cliceáil ar an nasc atá ar thaobh na láimhe deise ag barr gach iontrála. Breis eolais »

7 dtoradh

  1. PRODUCTION, TECHNOLOGY AND RESEARCH|technology and technical regulations|biotechnology

    #617665

    IATE #1073651
    leáphróitéin Tagairt Faomhadh an téarma seo mar chuid de Thionscadal Lex
    ga
    Fusionsprotein
    de
    fusion protein
    en
    Sainmhíniú protein created through the joining of two or more genes that originally coded for separate proteins Tagairt "Wikipedia > Fusion protein (18.6.2021)"
    protéine de fusion
    fr
    Sainmhíniú protéine chimère produite à partir de deux gènes recombinés in vitro, ou in vivo à la suite d'une translocation Tagairt Schorderet,D.,Gloss.génétique,Division de génétique médicale,CHUV,Lausanne,1993
  2. SOCIAL QUESTIONS|health|pharmaceutical industry

    #581780

    IATE #3542745
    glycylglycyl-L-proline (linker) fusion protein with enterotoxin type A (Staphylococcus aureus)-(1-33)-peptidyl-L-seryl[Ser36,Ser37,Glu38,Lys39,Ala41,Thr46,Thr71,Ala72,Ser75,Glu76,Glu78,Ser80,Ser81,Thr214,Ser217,Thr219,Ser220,Ser222,Ser224]enterotoxin type Tagairt Fiontar, DCU
    ga
    glycylglycyl-L-proline (linker) fusion protein with enterotoxin type A (Staphylococcus aureus)-(1-33)-peptidyl-L-seryl[Ser36,Ser37,Glu38,Lys39,Ala41,Thr46,Thr71,Ala72,Ser75,Glu76,Glu78,Ser80,Ser81,Thr214,Ser217,Thr219,Ser220,Ser222,Ser224]enterotoxin type E (Staphylococcus aureus)-(32-230)-peptide (synthetic superantigen SEA/E-120)
    en
  3. SOCIAL QUESTIONS|health|pharmaceutical industry|pharmaceutical product|vaccine

    #666322

    IATE #3621480
    vacsaín leáphróitéine Tagairt Faomhadh an téarma seo mar chuid de Thionscadal Lex
    ga
    vacsaín leápheiptíde Tagairt Faomhadh an téarma seo mar chuid de Thionscadal Lex
    ga
    fusion protein vaccine | fusion peptide vaccine
    en
    Sainmhíniú recombinant vaccine against a virus which targets the fusion proteins of the virus, i.e. those which mediate fusion of viral and cellular membranes Tagairt "COM-Terminology Coordination, based on: - Samantha Black. 'Variant-resistant COVID-19 vaccines could be effective, cheap to make' (19.10.2021). The Science Advisory Board. April 19, 2021- Molecular Targeting Technologies, Inc. (MTTI). 'Fusion Protein Vaccine Technology' (19.10.2021)"
  4. SOCIAL QUESTIONS|health|pharmaceutical industry

    #581826

    IATE #3542791
    L-lisil-L-alainil-L-seirilglicilglicín (nascóir) leáphróitéin le deis-(365-380)-[Asn364,Val407,Ser515,Gln590,Gln606,Arg613]eiseatocsain A(Pseudomonas aeruginosa)-(251-613)-peiptíd (tocsain le réigiún IA agus na chéad 16 iarmhair de réigiún IB scriosta) Tagairt Fiontar, DCU
    ga
    L-lysyl-L-alanyl-L-serylglycylglycine (linker) fusion protein with des-(365-380)-[Asn364,Val407,Ser515,Gln590,Gln606,Arg613]exotoxin A (Pseudomonas aeruginosa)-(251-613)-peptide (toxin with region IA and first 16 residues of region IB deleted)
    en
  6. SCIENCE|natural and applied sciences|life sciences|biology

    #665656

    IATE #3599595
    spícephróitéin réamhleá Tagairt Faomhadh an téarma seo mar chuid de Thionscadal Lex
    ga
    pre-fusion spike protein | pre-fusion S protein | prefusion spike protein | prefusion S protein
    en
    Sainmhíniú "spike protein of SARS-CoV-2 in its conformation before fusion of the virus and host cell membranes" Tagairt "COM-Terminology Coordination, based on: Proteopedia. 'SARS-CoV-2 spike protein fusion transformation' (18.6.2021)"
  7. SOCIAL QUESTIONS|health|pharmaceutical industry|pharmaceutical product|vaccine

    #665659

    IATE #3599599
    spícephróitéin réamhleá SARS-CoV-2 chobhsaithe Tagairt Faomhadh an téarma seo mar chuid de Thionscadal Lex
    ga
    stabilised SARS-CoV-2 pre-fusion S protein | SARS-CoV2 prefusion Spike delta TM
    en
    Sainmhíniú "pre-fusion spike protein of SARS-CoV-2 as it has been stabilised in order to be used in a vaccine" Tagairt "COM-Terminology Coordination, based on:- Paul A Goepfert, Bo Fu, Anne-Laure Chabanon, Matthew I Bonaparte, Matthew G Davis, Brandon J Essink, et al. 'Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1–2, dose-ranging study' (18.6.2021). Lancet Infect Dis. April 19, 2021- 'Supplementary appendix 2' (18.6.2021). Supplement to: Goepfert PA, Fu B, Chabanon A-L, et al. Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1–2, dose-ranging study. Lancet Infect Dis 2021; published online April 19. https://doi.org/10.1016/S1473-3099(21)00147-X"
    CoV2 preS dTM
    mul